Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 90,270

Document Document Title
WO/2018/131659A1
An immunotherapeutic agent containing a heterocyclic compound represented by general formula (I) or a metabolite or pharmaceutically acceptable salt thereof as an active ingredient.  
WO/2018/132369A1
The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.  
WO/2018/131963A1
Disclosed is an effect of ginsenoside compound K for inhibiting cytotoxic anticancer drug side-effects such as gastrointestinal disorders, bone marrow dysfunction, liver, kidney, and pancreatic dysfunction and the like.  
WO/2018/130840A1
The invention relates to the treatment and/or prevention of cardiovascular disease, for example thromboembolic conditions, such as atherothrombotic disease. In particularly, the invention relates to an arginine methylation inhibitor ('Ar...  
WO/2018/130178A1
A small molecule compound/combination for preventing, delaying, or reversing the aging of a cell, a tissue, an organ, or a body, and use thereof. The small molecule compound combination comprises at least one of a DNMT inhibitor, an HMT ...  
WO/2018/130702A1
The present invention relates tot he field of therapeutics and diagnostics. In particular, the present invention relates to a pharmaceutical composition or kit comprising (i) at least one CXCR4 inhibitorand (ii) a multi-tyrosine kinase i...  
WO/2018/131672A1
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonin nervous system- or dopamine nervous system-related diseases, in particular, mental dysfunction symptoms and other non-...  
WO/2018/132371A2
The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount suf...  
WO/2018/130928A1
A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acc...  
WO/2018/131626A1
The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention pro...  
WO/2018/127459A1
The invention relates to a dietary supplement preparation, which is present in particular in the form of a powder and/or as a concentrate, comprising: - a bioavailability component for increasing the bioavailability of dietary supplement...  
WO/2018/128173A1
The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treat...  
WO/2018/128939A1
Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-Ll are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific che...  
WO/2018/126303A1
Composition for treating human alcohol addiction or an alcoholic impulse control disorder or reducing the likelihood of relapse use of alcohol or practice of a behavior associated with an alcoholic impulse control disorder, said composit...  
WO/2018/129268A1
Provided herein are methods and related compositions for administering viral vectors and synthetic nanocarriers comprising an immunosuppressant. In some embodiments, the methods and compositions provided herein achieve improved transgene...  
WO/2018/127575A1
A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.  
WO/2018/129080A1
Methods are provided for treating a subject having a MYC-driven neoplasia. Aspects of the methods include administering to the subject an amount of an inhibitor of a target gene effective to treat the subject for the MYC-driven neoplasia...  
WO/2018/129556A1
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2018/127195A1
The present invention provides a substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof. Specifically, the present invention provides a compound represented by formula I, or a medicinal salt or a pr...  
WO/2018/128517A1
The present invention relates to: a composition containing niclosamide or pharmaceutically acceptable salts thereof as an active ingredient, for inhibiting Ras; and a pharmaceutical composition containing niclosamide or pharmaceutically ...  
WO/2018/129249A1
Provided herein are compositions and methods for the inhibition of enteric infection. In particular, compositions comprising bacteria of the class Clostridia are administered to human and/or animal subjects to prevent or decrease suscept...  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/122330A1
The present invention relates to a pharmaceutical composition comprising diclofenac or a pharmaceutically acceptable salt thereof in combination with eletriptan or a pharmaceutically acceptable salt thereof and at least one pharmaceutica...  
WO/2018/124386A1
The present invention relates to a pharmaceutical composition for preventing and treating tuberculosis, containing β-glucan and an anti-tuberculous drug as active ingredients. More specifically, the present invention provides a pharmace...  
WO/2018/123507A1
The present invention addresses the problem of providing a combination therapy which is effective in a cancer immunotherapy. The problem can be solved by providing an anti-tumor agent which contains DNA encoding WT1 protein and DNA encod...  
WO/2018/122845A1
The present invention provides safe, low-dose, therapeutic combinations of CNS drugs with peripheral adrenergic receptor agonists, and their use in methods for treating various conditions.  
WO/2018/121560A1
The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described ...  
WO/2018/122168A1
The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of Bub1 kinase, and component B being a PARP inhibitor. Another aspect of the present invention relates...  
WO/2018/124011A1
The purpose of the present invention is to provide a motor control function improving agent that improves motor control functions which have deteriorated due to aging or fatigue, and a method for evaluating or selecting the motor control...  
WO/2018/120610A1
A Leg1 protein, a Leg1 gene, applications of the Leg1 protein and the Leg1 gene, and a drug. A mLeg1 gene knockout mouse is used as a research subject. A comprehensive research of the function of the mLeg1 gene is made by means of geneti...  
WO/2018/124835A1
The present invention provides a recombinant exosome having phagocytosis-promoting protein presented on the surface thereof and the use thereof.  
WO/2018/124468A1
The present invention relates to a dapagliflozin L-proline-containing pharmaceutical composition. Specifically, the dapagliflozin L-proline-containing pharmaceutical composition, according to the present invention, exhibits excellent elu...  
WO/2018/123680A1
In order to provide a novel means for ameliorating mastitis or improving milk production, the present invention provides a mastitis ameliorating or treating agent or a milk production promoting agent that contains a biosurfactant.  
WO/2018/123999A1
[Problem] To provide a method for selecting individuals for whom administration of an immune checkpoint inhibitor would be effective, by extracting tumor tissue from individuals who have developed tumors and determining the level of expr...  
WO/2018/124236A1
Provided is a medicinal composition to be used for treating an intractable heart tissue fibrosis disease accompanying chronic heart failure. The medicinal composition, which is to be used for treating an intractable heart tissue fibrosis...  
WO/2018/122385A1
The present invention relates to pharmaceutical compositions comprising metformin hydrochloride and pioglitazone hydrochloride.  
WO/2018/124010A1
The purpose of the present invention is to provide a cognitive function improving agent that effectively improves cognitive functions such as memory and learning, and a method for evaluating or selecting said cognitive function improving...  
WO/2018/124009A1
The purpose of the present invention is to provide a prophylactic or ameliorating agent for hypothermia which is effective against hypothermia. Specifically provided is a prophylactic or ameliorating agent for hypothermia which compris...  
WO/2018/124497A1
The present invention relates to a pharmaceutical composite preparation containing dapagliflozin L-proline and at least one antidiabetic agent. Specifically, the present invention provides a pharmaceutical composite preparation containin...  
WO/2018/117090A1
Provided is a method for inducing a regulatory T cell, comprising a step of suppressing the expression of Satb1 or suppressing the function of Satb1 in a normal peripheral T cell. When the expression of Satb1 in a normal peripheral T cel...  
WO/2018/114965A1
The present invention relates to antibiotic compounds and their use as ClpX inhibitors and in the treatment of bacterial infections, such as infections with multi-resistant Staphylococcus aureas, and in the treatment of leukemia. The pre...  
WO/2018/115013A1
The present invention is directed to compositions comprising a pulmonary surfactant in combination with a corticosteroid for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates and methods thereof.  
WO/2018/118587A1
Provided are antiviral compositions that use a CRISPR-associated (Cas) endonuclease and a guide RNA that work together to eliminate viral nucleic acid from host cells, e.g., human cells. The guide RNA includes a target sequence complemen...  
WO/2018/118586A1
Compositions include a nuclease and other agents that work together to not only digest viral nucleic acid but also to prevent human genes from being used to maintain the viral episome. Compositions may include a programmable nuclease suc...  
WO/2018/116201A1
The present invention relates to myostatin or activin antagonists or receptor antagonists for use in improving body composition, e.g., for the treatment of central adiposity, obesity or overweight condition and related comorbidities. The...  
WO/2018/116293A1
The present invention provides low-dose, synergistic combinations of NMDA receptor antagonists and peripheral adrenergic receptor agonists, and methods for their use in preventing and treating hypoxia and neuronal damage.  
WO/2018/118626A1
Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia compr...  
WO/2018/117177A1
The present invention relates to a Brk inhibitor compound represented by general formula (I) (wherein all the symbols are as defined in the description), a salt of the compound, an N-oxide of the compound, a solvate of the compound, or a...  
WO/2018/115458A1
Oncolytic herpes simplex virus for use in a method of treating cancer in a pediatric subject having a tumor are described, wherein the oncolytic herpes simplex virus is administered intratumorally.  
WO/2018/119080A1
The present disclosure describes novel methods for treating a subject with a hepatic disorder. Specifically, the methods include the administration of an S1P1-selective agent to a subject in order to stimulate liver tissue development, v...  

Matches 1 - 50 out of 90,270